Boron Compound Active Ingredients TRIZ Cases
- Seco-Rapamycin and Proteasome Inhibitors for Resistant Cancer
Combining seco-rapamycin with bortezomib overcomes drug resistance in lung, ovarian, and breast cancers by disrupting multiple survival pathways.
- Benzothiophen-2-yl Boronate Synthesis via Mild Catalyst System
A modified synthetic pathway employs a metal halide and Lewis base catalyst system to prepare benzothiophen-2-yl boronates under moderate temperatures.
- Bortezomib Aqueous Formulation Stability via Polyhydroxy Excipients
Polyhydroxy excipients stabilize bortezomib in aqueous solutions, eliminating reconstitution steps and extending storage life.
- BH3 Mimetic Compounds Targeting Mcl-1 to Overcome B-cell Lymphoma Resistance
BH3 mimetic compounds block Mcl-1 mediated resistance mechanisms, restoring chemotherapy sensitivity and improving survival outcomes.
- Selective Alpha-Amino Boronic Acid Inhibitors for LMP7
Alpha-amino boronic acid derivatives selectively inhibit the immunoproteasome subunit LMP7, reducing side effects from broad proteasome inhibition.